Roflumilast—an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial

Halbert, 2003, Interpreting COPD prevalence estimates: what is the true burden of disease?, Chest, 123, 1684, 10.1378/chest.123.5.1684

Murray, 1997, Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study, Lancet, 349, 1498, 10.1016/S0140-6736(96)07492-2

Pauwels, 2004, Burden and clinical features of chronic obstructive pulmonary disease (COPD), Lancet, 364, 613, 10.1016/S0140-6736(04)16855-4

2004

Calverley, 2003, Chronic obstructive pulmonary disease, Lancet, 362, 1053, 10.1016/S0140-6736(03)14416-9

Viegi, 2001, Epidemiology of chronic obstructive pulmonary disease (COPD), Respiration, 68, 4, 10.1159/000050456

Hogg, 2004, Pathophysiology of airflow limitation in chronic obstructive pulmonary disease, Lancet, 364, 709, 10.1016/S0140-6736(04)16900-6

Barnes, 2003, Chronic obstructive pulmonary disease: molecular and cellular mechanisms, Eur Respir J, 22, 672, 10.1183/09031936.03.00040703

Barnette, 1999, Phosphodiesterase 4 (PDE4) inhibitors in asthma and chronic obstructive pulmonary disease (COPD), Prog Drug Res, 53, 193, 10.1007/978-3-0348-8735-9_5

Compton, 2001, Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study, Lancet, 358, 265, 10.1016/S0140-6736(01)05481-2

Bundschuh, 2001, In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor, J Pharmacol Exp Ther, 297, 280

Hatzelmann, 2001, Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro, J Pharmacol Exp Ther, 297, 267

Lipworth, 2005, Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease, Lancet, 365, 167, 10.1016/S0140-6736(05)17708-3

2001

1995, Standardization of spirometry, 1994 update, Am J Respir Crit Care Med, 152, 1107, 10.1164/ajrccm.152.3.7663792

Quanjer, 1993, Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society, Eur Respir J Suppl, 16, 5, 10.1183/09041950.005s1693

Jones, 1992, A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire, Am Rev Respir Dis, 145, 1321, 10.1164/ajrccm/145.6.1321

Szafranski, 2003, Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease, Eur Respir J, 21, 74, 10.1183/09031936.03.00031402

Calverley, 2003, Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial, Lancet, 361, 449, 10.1016/S0140-6736(03)12459-2

Hansen, 2001, Peak flow as predictor of overall mortality in asthma and chronic obstructive pulmonary disease, Am J Respir Crit Care Med, 163, 690, 10.1164/ajrccm.163.3.2006120

Grootendorst, 2003, Does a single dose of the phosphodiesterase 4 inhibitor, cilomilast (15 mg), induce bronchodilation in patients with chronic obstructive pulmonary disease?, Pulm Pharmacol Ther, 16, 115, 10.1016/S1094-5539(02)00172-4

Engelstätter, 2005, Roflumilast, an oral, once-daily phosphodiesterase 4 (PDE4) inhibitor, does not exhibit bronchodilatory activity, Ann Allergy Asthma Immunol, 94, 169

Kumar, 2003, Inhibition of inflammation and remodeling by roflumilast and dexamethasone in murine chronic asthma, J Pharmacol Exp Ther, 307, 349, 10.1124/jpet.103.053819

Muise, 2002, Comparison of inhibition of ovalbumin-induced bronchoconstriction in guinea pigs and in vitro inhibition of tumor necrosis factor-alpha formation with phosphodiesterase 4 (PDE4) selective inhibitors, Biochem Pharmacol, 63, 1527, 10.1016/S0006-2952(02)00903-6

Timmer, 2002, The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-α ex vivo, J Clin Pharmacol, 42, 297, 10.1177/00912700222011328

1999

Calverley, 2003, Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease, Eur Respir J, 22, 912, 10.1183/09031936.03.00027003

Casaburi, 2002, A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease, Eur Respir J, 19, 217, 10.1183/09031936.02.00269802

Donohue, 2002, A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol, Chest, 122, 47, 10.1378/chest.122.1.47

Burge, 2000, Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial, BMJ, 320, 1297, 10.1136/bmj.320.7245.1297

O'Donnell, 1994, Breathlessness in patients with chronic airflow limitation: mechanisms and management, Chest, 106, 904, 10.1378/chest.106.3.904

Swanney, 2000, FEV(06) is an acceptable surrogate for FVC in the spirometric diagnosis of airway obstruction and restriction, Am J Respir Crit Care Med, 162, 917, 10.1164/ajrccm.162.3.9907115

O'Donnell, 1999, Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease, Am J Respir Crit Care Med, 160, 542, 10.1164/ajrccm.160.2.9901038